Treatment With Nefecon Reduces Circulating Levels of Galactose- Deficient IgA1 in Patients With IgA Nephropathy in the NefIgArd Clinical Trial

Category Primary study
JournalJournal of the American Society of Nephrology
Year 2022
This article has no abstract
Epistemonikos ID: 3b951534147c04d069158cbfa0033c78528910d0
First added on: Feb 15, 2025